Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial

JAMA Pediatrics

Volumn 167, Issue 11, 2013, Pages 1045-1052

  King, Bryan H ^a,b   Dukes, Kimberly ^c   Donnelly, Craig L ^d   Sikich, Linmarie ^e   McCracken, James T ^f   Scahill, Lawrence ^g   Hollander, Eric ^h   Bregman, Joel D ⁱ   Anagnostou, Evdokia ^j   Robinson, Fay ^c   Sullivan, Lisa ^k   Hirtz, Deborah ^l  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c DM STAT Inc   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ Center for Autism   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k BOSTON UNIVERSITY   (United States)

^l NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; FLUVOXAMINE; HUMAN IMMUNOGLOBULIN; METHYLPHENIDATE; OLANZAPINE; PLACEBO; RISPERIDONE; SECRETIN; VALPROATE SEMISODIUM; VALPROIC ACID; SEROTONIN UPTAKE INHIBITOR;

ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; AGE; ARTICLE; ASPERGER SYNDROME; AUTISM; CAREGIVER BURDEN; CHECKLIST; CHILD; CHILD AND ADOLESCENT SYMPTOM INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; COMPULSION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PLACEBO EFFECT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVISED REPETITIVE BEHAVIOR SCALE; SCHOOL CHILD; VINELAND ADAPTIVE BEHAVIOR SCALE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CLINICAL TRIAL; FEMALE; MALE; MULTICENTER STUDY; PRINCIPAL COMPONENT ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ASPERGER SYNDROME; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CITALOPRAM; FEMALE; HUMANS; MALE; PLACEBO EFFECT; PRINCIPAL COMPONENT ANALYSIS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84888861958     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.2698     Document Type: Article

References (45)

1. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2007;17(3):348-355.
2. Mogar RE, Aldrich RW. The use of psychedelic agents with autistic schizophrenic children. Behav Neuropsychiatry. 1969;1(8):44-50.
3. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9-15.
4. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil. 2005;26(1):87-97.
5. Krishnaswami S, McPheeters ML, Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1322-e1325.
6. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658-665.
7. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540.
8. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119.
9. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205.
10. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990-998.
11. King BH, Hollander E, Sikich L, et al; STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583-590.
12. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001-1008.
13. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274.
14. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-548.
15. Handen BL, Melmed RD, Hansen RL, et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 2009;39(5):796-805.
16. Buitelaar JK, Dekker ME, van Ree JM, van Engeland H. A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism. Eur Neuropsychopharmacol. 1996;6(1):13-19.
17. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633-641.
18. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-455.
19. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37(2):367-373.
20. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
21. Carey T, Ratliff-Schaub K, Funk J, Weinle C, Myers M, Jenks J. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. J Autism Dev Disord. 2002;32(3):161-167.
22. Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord. 2000;30(2):87-94.
23. Coniglio SJ, Lewis JD, Lang C, et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001;138(5):649-655.
24. Dunn-Geier J, Ho HH, Auersperg E, et al. Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol. 2000;42(12):796-802.
25. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341(24):1801- 1806.
26. Sponheim E, Oftedal G, Helverschou SB. Multiple doses of secretin in the treatment of autism: a controlled study. Acta Paediatr. 2002;91(5):540-545.
27. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(4):682-692.
28. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry. 2009;166(1):42-49.
29. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: ameta-analysis. BMJ. 1995;310(6984):897-901.
30. Cohen D, Consoli A, Bodeau N, et al. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol. 2010;20(1):39-47.
31. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
32. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: ameta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
33. Khan A, Bhat A, Faucett J, Kolts R, Brown WA. Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. Psychopharmacology (Berl). 2011;214(4):961-965.
34. Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev. 2005;11(2):164-170.
35. Arnold LE, Farmer C, Kraemer HC, et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol. 2010;20(2):83-93.
36. Gadow KD, Sprafkin J. Child Symptom Inventory 4: Screening and Norms Manual. Stony Brook, NY: Checkmate Plus; 2002.
37. Garcia AM, Sapyta JJ, Moore PS, et al. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry. 2010;49(10):1024-1033; quiz 1086.
38. Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211-218.
39. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976.
40. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485-491.
41. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30(3):237-243.
42. Scahill L, McDougle CJ, Williams SK, et al; Research Units on Pediatric Psychopharmacology Autism Network. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114-1123.
43. Sparrow S, Balla D, Cicchetti D. Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service; 1984.
44. Brannan AM, Heflinger CA, Bickman L. The Caregiver Strain Questionnaire: measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord. 1997;5(4):212-222. doi:10.1177/ 106342669700500404.
45. Warren Z, Veenstra-Vander Weele J, Stone W, et al. Therapies for children with autism spectrum disorders. AHRQ Comparative Effectiveness Reviews. 2011:Report No.: 11-EHC029-EF.